ShedRx semaglutide: November 2026 price and position
As of November 20, 2026, ShedRx’s page shows compounded semaglutide from $159 ("GLP-1s from $159/mo" (drug not named)) but no month-to-month price, so its regular monthly cost could not be confirmed. Ask for the all-in price at your dose before paying.
Released · Last reviewed · how we verify
ShedRx semaglutide prices, read November 20, 2026
| Measure | Amount | Basis |
|---|---|---|
| Month to month, all-in | from $159 | lowest printed: "GLP-1s from $159/mo" (drug not named); no month-to-month figure |
| Lowest printed rate | $159 | "GLP-1s from $159/mo" (drug not named) |
Limitations and what to check before you enroll
Compounded semaglutide is not FDA-approved and is not the same product as Wegovy; it is made for an individual patient by a state-licensed pharmacy. Ask ShedRx for the all-in price at the maintenance dose, what is charged today and how often, and which pharmacy fills the prescription. A clinician decides whether any GLP-1 is right for you.
Frequently asked
How much does ShedRx charge for semaglutide?
As of November 20, 2026, ShedRx’s page shows compounded semaglutide from $159 ("GLP-1s from $159/mo" (drug not named)) but no month-to-month price, so its regular monthly cost could not be confirmed. Ask for the all-in price at your dose before paying.
Is ShedRx’s semaglutide FDA-approved?
No. Compounded semaglutide from any telehealth program, ShedRx included, is not FDA-approved and is not the same product as Wegovy or Ozempic. It is made for an individual patient by a state-licensed compounding pharmacy. Brand Wegovy is the FDA-approved version.
Where do these ShedRx figures come from?
From ShedRx’s own page (first-party read, November 20, 2026), converted to an all-in month-to-month figure (medication plus any required recurring fee, before tax). The source link and read date are listed below, and the same figures are in the open dataset.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)
- ShedRx pricing page (read November 20, 2026)